Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HRH2 | P25021 | 2/20 | 0.40 |
| ▸ | HRH1 | P35367 | 2/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | PREP | P48147 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 3/20 | 0.37 |
| ▸ | CTSK | P43235 | 4/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24698048 | 0.87 | ELANE (0.49) | KMT2AHRH2HRH1ELANECA1 | |
| SCHEMBL21124846 | 0.86 | KMT2A (0.40) | KMT2AHRH2HRH1CA1CA2 | |
| SCHEMBL25954752 | 0.86 | ELANE (0.38) | KMT2AELANECA1CA2CA7 | |
| SCHEMBL25650684 | 0.86 | ELANE (0.38) | KMT2AELANECA1CA2CA7 | |
| SCHEMBL9101167 | 0.83 | KMT2A (0.43) | KMT2AHRH2HRH1ELANECA1 | |
| SCHEMBL9101170 | 0.83 | KMT2A (0.43) | KMT2AHRH2HRH1ELANECA1 | |
| SCHEMBL18212483 | 0.82 | KMT2A (0.48) | KMT2AHRH2HRH1ELANECA1 | |
| SCHEMBL18212459 | 0.82 | KMT2A (0.45) | KMT2AHRH2HRH1ELANECA1 | |
| SCHEMBL28673312 | 0.82 | KMT2A (0.48) | KMT2AHRH2HRH1ELANECA1 | |
| SCHEMBL24425262 | 0.81 | HDAC4 (0.41) | ELANECA1CA2CTSLCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3291810-B1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2022-08-10 | — | — | EP | disclosed |
| WO-2016179554-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. (US) | 2016-11-10 | — | — | WO | disclosed |
| US-20160326124-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2016-11-10 | — | — | US | disclosed |
| US-20160326124-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2016-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326124-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | HDAC1, HDAC7, HDAC5 | KMT2A 84/4885HRH2 1370/4885HRH1 1933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.